The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Drug rechallenge and treatment beyond progression—implications for drug resistance
Open accessAbstract
The established dogma in oncology for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant. Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated. Over the past few decades, clinical evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents. There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy. Additional, albeit limited, evidence suggests that, in certain circumstances, continuing a therapy beyond disease progression can also have antitumour activity. In this Review, we describe the anticancer agents used in these treatment strategies and discuss the potential mechanisms explaining the apparent tumour re-sensitization with reintroduced or continued therapy. The extensive number of malignancies and drugs that challenge the custom of permanently switching to different drugs at each line of therapy warrants a more in-depth examination of the definitions of disease progression and drug resistance and the resulting implications for patient care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Self-citationThe National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 2×
“…+ lapatinib Blackwell 2010 (phase III) Von Minckwitz 2009 (phase III) Capecitabine Trastuzumab + capecitabine Cetuximab Irinotecan + cetuximab Cunningham 2004 (phase II) Irinotecan/oxaliplatin chemotherapy Bennouna 2013 (phase III) Bevacizumab + irinotecan/oxaliplatin chemotherapy Lapatinib…”
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Wolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Mahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
DQIS Research Group (2026) · PubMed · doi:10.5281/zenodo.21937949 · Cited by 1,327
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H., Sledge, G., Koehler, M., Ellis, C., Casey, M., Vukelja, S., Bischoff, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4437 · Cited by 942
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
Tournigand, C., Cervantes, A., Figer, A., Lledo, G., Flesch, M., Buyse, M., Mineur, L., Carola, E., Etienne, P.-L., Rivera, F., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0106 · Cited by 805
A Southwest Oncology Group study
Jenkins, T. R., Tangen, C. M., Macdonald, J. S., Weiss, G. R., Chapman, R. M., & Hantel, A. (1993) · Cited by 773
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M. K., Ng, K., Ma, J., Wienholds, E., Dunant, C., et al. (2013) · Science · doi:10.1126/science.1227670 · Cited by 744
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., Dummer, R., McMahon, M., & Stuart, D. D. (2013) · Nature · doi:10.1038/nature11814 · Cited by 730
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Engelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
Pegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Grothey, A., Sugrue, M. M., Purdie, D. M., Dong, W., Sargent, D., Hedrick, E., & Kozloff, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3212 · Cited by 688
Self-citationRepopulation of cancer cells during therapy: an important cause of treatment failure
Kim, J. J., & Tannock, I. F. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1650 · Cited by 686
Reduced permeability in CHO cells as a mechanism of resistance to colchicine
Ling, V., & Thompson, L. H. (1974) · Journal of Cellular Physiology · doi:10.1002/jcp.1040830114 · Cited by 686
von Minckwitz, G., du Bois, A., Schmidt, M., Maass, N., Cufer, T., de Jongh, F. E., Maartense, E., Zielinski, C., Kaufmann, M., Bauer, W., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.6618 · Cited by 676
Rothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Quintana, E., Shackleton, M., Foster, H. R., Fullen, D. R., Sabel, M. S., Johnson, T. M., & Morrison, S. J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.012 · Cited by 599
Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., Milo, R., Cohen-Saidon, C., Liron, Y., Kam, Z., et al. (2008) · Science · doi:10.1126/science.1160165 · Cited by 596
Blackwell, K. L., Burstein, H. J., Storniolo, A. M., Rugo, H. S., Sledge, G., Aktan, G., Ellis, C., Florance, A., Vukelja, S., Bischoff, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6725 · Cited by 547
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
Chmielecki, J., Foo, J., Oxnard, G. R., Hutchinson, K., Ohashi, K., Somwar, R., Wang, L., Amato, K. R., Arcila, M., Sos, M. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002356 · Cited by 525
[Hypercoagulability and exanthematous Mediterranean fever].
Vicente, V., Moraleda, J. M., Herrero, I., & Ruiz, R. (1991) · PubMed · Cited by 493
Medicine, N. L. O. (2008) · Journal of Pain & Palliative Care Pharmacotherapy · doi:10.1080/15360280801989377 · Cited by 468
Chibaudel, B., Maindrault-Goebel, F., Lledo, G., Mineur, L., André, T., Bennamoun, M., Mabro, M., Artru, P., Carola, E., Flesch, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4344 · Cited by 395
Blay, J.-Y., Le Cesne, A., Ray-Coquard, I., Bui, B., Duffaud, F., Delbaldo, C., Adenis, A., Viens, P., Rios, M., Bompas, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0183 · Cited by 392
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J., & Salmon, S. E. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.1.17 · Cited by 384
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
Perry, J. R., Bélanger, K., Mason, W. P., Fulton, D., Kavan, P., Easaw, J., Shields, C., Kirby, S., Macdonald, D. R., Eisenstat, D. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5520 · Cited by 384
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question
Fojo, T., & Grady, C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp177 · Cited by 349
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
Teicher, B., Herman, T., Holden, S., Wang, Y., Pfeffer, M., Crawford, J., & Frei, E. (1990) · Science · doi:10.1126/science.247.4949.1457 · Cited by 327
Modulation of multidrug-resistant multiple myeloma by cyclosporin
Sonneveld, P., Lowenberg, B., Durie, B. G. M., Lokhorst, H. M., Marie, J.-P., Zittoun, R., Solbu, G., Suciu, S., & Nooter, K. (1992) · The Lancet · doi:10.1016/0140-6736(92)92353-h · Cited by 316
Le Cesne, A., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., Duffaud, F., Chevreau, C., Cupissol, D., Cioffi, A., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70222-9 · Cited by 294
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Tripathy, D., Slamon, D. J., Cobleigh, M., Arnold, A., Saleh, M., Mortimer, J. E., Murphy, M., & Stewart, S. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.557 · Cited by 280
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line.
Zijlstra, J. G., de Vries, E. G. E., & Mulder, N. H. (1987) · PubMed · Cited by 265
Adams, R. A., Meade, A. M., Seymour, M. T., Wilson, R. H., Madi, A., Fisher, D., Kenny, S. L., Kay, E., Hodgkinson, E., Pope, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70102-4 · Cited by 264
Simon, G. R., & Wagner, H. (2003) · Chest · doi:10.1378/chest.123.1_suppl.259s · Cited by 221
Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G., Scartozzi, M., Mancuso, A., Frezza, A. M., Venditti, O., Imperatori, M., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr623 · Cited by 211
A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma
Sivanand, S., Peña-Llopis, S., Zhao, H., Kucejova, B., Spence, P., Pavia-Jimenez, A., Yamasaki, T., McBride, D. J., Gillen, J., Wolff, N. C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003643 · Cited by 193
Maughan, T., James, R., Kerr, D., Ledermann, J., Seymour, M., Topham, C., McArdle, C., Cain, D., & Stephens, R. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12461-0 · Cited by 191
Mechanisms and implications of imatinib resistance mutations in BCR-ABL
Nardi, V., Azam, M., & Daley, G. Q. (2004) · Current Opinion in Hematology · doi:10.1097/00062752-200401000-00006 · Cited by 191
Gennari, A., Stockler, M., Puntoni, M., Sormani, M., Nanni, O., Amadori, D., Wilcken, N., D'Amico, M., DeCensi, A., & Bruzzi, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5374 · Cited by 186
Dalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · doi:10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r · Cited by 175
Kobayashi, S., Yamada‐Okabe, H., Suzuki, M., Natori, O., Kato, A., Matsubara, K., Jau Chen, Y., Yamazaki, M., Funahashi, S., Yoshida, K., et al. (2012) · STEM CELLS · doi:10.1002/stem.1257 · Cited by 175
Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1106 · Cited by 173
Yu, M., Ocaña, A., & Tannock, I. F. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9402-8 · Cited by 150
Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer
de Gramont, A., Buyse, M. E., Abrahantes, J. C., Burzykowski, T., Quinaux, E., Cervantes, A. M. R., Figer, A., Lledo, G., Flesch, M., Mineur, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.4380 · Cited by 146
Solit, D. B., She, Y., Lobo, J. M., Kris, M. G., Scher, H. I., Rosen, N. X., & Sirotnak, F. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1347 · Cited by 138
Sunitinib rechallenge in metastatic renal cell carcinoma patients
Zama, I. N., Hutson, T. E., Elson, P. J., Cleary, J. M., Choueiri, T. K., Heng, D. Y. C., Ramaiya, N. H., Michaelson, M. D., Garcia, J. A., Knox, J. J., et al. (2010) · Cancer · doi:10.1002/cncr.25583 · Cited by 137
Treatment selection in metastatic renal cell carcinoma: expert consensus
Escudier, B. J., Szczylik, C. A., Porta, C., & Gore, M. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.59 · Cited by 136
Haber, D. A., & SCHIMKE, R. T. (1981) · Cell · doi:10.1016/0092-8674(81)90204-x · Cited by 136
Petrucci, M. T., Giraldo, P., Corradini, P., Teixeira, A., Dimopoulos, M. A., Blau, I. W., Drach, J. W., Angermund, R., Allietta, N., Broer, E., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12198 · Cited by 128
Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule
Perry, J., Rizek, P., Cashman, R. L., Morrison, M., & Morrison, T. (2008) · Cancer · doi:10.1002/cncr.23813 · Cited by 122
Becker, A., Crombag, L., Heideman, D. A. M., Thunnissen, F. B., van Wijk, A. W., Postmus, P. E., & Smit, E. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.046 · Cited by 117
Hashimoto, K., Man, S., Xu, P., Cruz‐Muñoz, W., Tang, T., Kumar, R., & Kerbel, R. S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0960 · Cited by 113
Self-citationRechallenge with temozolomide in patients with recurrent gliomas
Wick, A., Pascher, C., Wick, W., Jauch, T., Weller, M., Bogdahn, U., & Hau, P. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5006-9 · Cited by 108
Nishie, K., Kawaguchi, T., Tamiya, A., Mimori, T., Takeuchi, N., Matsuda, Y., Omachi, N., Asami, K., Okishio, K., Atagi, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826913f7 · Cited by 107
Extra, J.-M., Antoine, É.-C., Vincent‐Salomon, A., Delozier, T., Kerbrat, P., Béthune-Volters, A., Guastalla, J., Spielmann, M., Mauriac, L., Misset, J. L., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0029 · Cited by 107
Effect of re-treatment with gefitinib (‘Iressa’, ZD1839) after acquisition of resistance
Kurata, T., Tamura, K., Kaneda, H., Nogami, T., Uejima, H., Asai, G., Nakagawa, K., & Fukuoka, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh006 · Cited by 107
Yano, S., Nakataki, E., Ohtsuka, S., Inayama, M., Tomimoto, H., Edakuni, N., Kakiuchi, S., Nishikubo, N., Muguruma, H., & Sone, S. (2005) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504005775082020 · Cited by 99
Eymard, J., Oudard, S. M., Gravis, G., Ferrero, J.-., Théodore, C., Joly, F., Priou, F., Krakowski, I., Zannetti, A., Thill, L., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09296.x · Cited by 99
Maindrault‐Gœbel, F., Tournigand, C., André, T., Carola, É., Mabro, M., Artru, P., Louvet, C., & de Gramont, A. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh305 · Cited by 98
Intermittent chemotherapy in patients with metastatic androgen‐independent prostate cancer
Beer, T. M., Ryan, C. W., Venner, P. M., Petrylak, D. P., Chatta, G. S., Ruether, J. D., Chi, K. N., Young, J. A., & Henner, W. D. (2007) · Cancer · doi:10.1002/cncr.23163 · Cited by 95
Sonneveld, P., Suciu, S., Weijermans, P., Beksaç, M., Neuwirtová, R., Solbu, G., Lokhorst, H. M., der Lelie, J. V., Döhner, H., Gerhartz, H., et al. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03171.x · Cited by 93
Shulman, L. N., Cirrincione, C., Berry, D. A., Becker, H. P., Perez, E. A., O'Regan, R. M., Martino, S., Atkins, J. N., Mayer, E. L., Schneider, C. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.6405 · Cited by 93
Unmaintained remissions in multiple myeloma
Alexanian, R., Gehan, E. A., Haut, A., Saiki, J. H., & Weick, J. K. (1978) · Blood · doi:10.1182/blood.v51.6.1005.1005 · Cited by 93
Reardon, D. A., Herndon, J. E., Peters, K. B., Desjardins, A., Coan, A., Lou, E., Sumrall, A. L., Turner, S., Lipp, E., Sathornsumetee, S., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.415 · Cited by 90
Lorenzo, G. D., Buonerba, C., Faiella, A., Rescigno, P., Rizzo, M., Riccardo Autorino, B., Perdonà, S., Riccardi, F., Scagliorini, S., Scognamiglio, F., et al. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09498.x · Cited by 88
Loriot, Y., Massard, C., Gross‐Goupil, M., Palma, M. D., Escudier, B. J., Bossi, A., Chauchereau, A., & Fizazi, K. S. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.04.010 · Cited by 87
Rimawi, M. F., Wiechmann, L., Wang, Y.-C., Huang, C., Migliaccio, I., Wu, M.-F., Gutiérrez, C., Hilsenbeck, S. G., Arpino, G., Massarweh, S. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1905 · Cited by 87
Guérin, É., Man, S., Xu, P., & Kerbel, R. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4183 · Cited by 86
Self-citationCara, S., & Tannock, I. F. (2001) · Annals of Oncology · doi:10.1023/a:1008389706725 · Cited by 86
Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy
Colombo, N., & Gore, M. E. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.04.004 · Cited by 85
Salvage temozolomide for prior temozolomide responders
Franceschi, E., Omuro, A. M. P., Lassman, A. B., Demopoulos, A. M., Nolan, C. P., & Abrey, L. E. (2005) · Cancer · doi:10.1002/cncr.21564 · Cited by 83
Yokouchi, H., Yamazaki, K., Kinoshita, I., Konishi, J. S., Asahina, H., Sukoh, N., Harada, M., Akie, K., Ogura, S., Ishida, T., et al. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-51 · Cited by 82
Lee, D. H., Kim, S.-W., Suh, C. H., Yoon, D. H., Yi, E. J., & Lee, J.-S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn423 · Cited by 80
Tang, T., Man, S., Xu, P., Francia, G., Hashimoto, K., Emmenegger, U., & Kerbel, R. S. (2010) · Neoplasia · doi:10.1593/neo.10804 · Cited by 78
Self-citationZhang, L., Bhasin, M., Schor-Bardach, R., Wang, X., Collins, M. P., Panka, D. J., Putheti, P., Signoretti, S., Alsop, D. C., Libermann, T. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019144 · Cited by 78
Oh, I., Ban, H., Kim, K., & Kim, Y. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.012 · Cited by 75
Morales, C., García, M. J., Ribas, M., Miró, R., Muñoz, M., Caldas, C., & Peinado, M. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0759 · Cited by 73
Kong, D., Lee, J.-I., Kim, W. K., Son, M. J., Lim, D. H., Kim, S. H., Park, K., Kim, J. W., Eoh, W., & Nam, D. (2006) · Oncology Reports · doi:10.3892/or.16.5.1117 · Cited by 70
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
Palmieri, C., Krell, J., James, C. R., Harper-Wynne, C. L., Misra, V., Cleator, S. J., & Miles, D. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.122 · Cited by 67
Italiano, A., Cioffi, A., Coco, P., Maki, R. G., Schöffski, P., Rutkowski, P. L., Cesne, A. L., Duffaud, F., Adenis, A., Isambert, N., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2120-6 · Cited by 61
Tomizawa, Y., Fujita, Y., Tamura, A., Shirai, M., Shibata, S., Kawabata, T., Shibayama, T., Fukai, S., Kawahra, M., & Saito, R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2009.06.025 · Cited by 61
Cancello, G., Montagna, E., D’Agostino, D., Giuliano, M., Giordano, A., Lorenzo, G. D., Plaitano, M., Placido, S. D., & Laurentiis, M. D. (2008) · Breast Cancer Research · doi:10.1186/bcr2119 · Cited by 59
Goh, H., Kim, Y., Kim, D., Kim, H., Kim, S., Jang, S., Lee, J. E., Kim, D., Kim, W.-S., Park, S.-H., et al. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902926973 · Cited by 57
He, K., Xu, T., & Goldkorn, A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1120 · Cited by 57
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer
Šeruga, B., & Tannock, I. F. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1180 · Cited by 57
Stopping Treatment Can Reverse Acquired Resistance to Letrozole
Sabnis, G. J., Macedo, L. F., Goloubeva, O. G., Schayowitz, A., & Brodie, A. M. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5999 · Cited by 56
Faehling, M., Eckert, R., Kamp, T., Kuom, S., Griese, U., Sträter, J., Ott, G., & Spengler, W. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.02.010 · Cited by 51
Weisberg, E., Ray, A., Nelson, E. A., Adamia, S., Barrett, R., Sattler, M., Zhang, C., Daley, J. F., Frank, D. A., Fox, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025351 · Cited by 50
Hrusovsky, I., Emmerich, B., von Rohr, A., Voegeli, J., Taverna, C., Olie, R. A., Pliskat, H., Frohn, C., & Hess, G. (2010) · Oncology · doi:10.1159/000322866 · Cited by 48
Asahina, H., Oizumi, S., Inoue, A., Kinoshita, I., Ishida, T., Fujita, Y., Sukoh, N., Harada, M., Maemondo, M., Saijo, Y., et al. (2010) · Oncology · doi:10.1159/000326488 · Cited by 48
Petrelli, F., & Barni, S. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.11.008 · Cited by 40
Body weight, serum cholesterol, and stage of primary breast cancer
Howson, C. P., Kinne, D. W., & Wynder, E. L. (1986) · Cancer · doi:10.1002/1097-0142(19861201)58:11<2546::aid-cncr2820581131>3.0.co;2-n · Cited by 36
Sorafenib rechallenge in patients with metastatic renal cell carcinoma
Nozawa, M., Yamamoto, Y., Minami, T., et al. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10905.x · Cited by 31
Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors
Bracci, R., Maccaroni, E., & Cascinu, S. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1301237 · Cited by 30
Grothey, A. F. (2010) · Oncology · doi:10.1159/000323491 · Cited by 29
Self-citationMuss, H. B., Smith, L. R., & Cooper, M. R. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1556 · Cited by 26
Campiglio, M., Bufalino, R., Sandri, M. F., Ferri, E., Aiello, R. A., Matteis, A. D., Mottolese, M., Placido, S. D., Querzoli, P., Jirillo, A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1484-4 · Cited by 25
Effective response with bortezomib retreatment in relapsed multiple myeloma
Taverna, C., Voegeli, J., Trojan, A., Olie, R. A., & von Rohr, A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13562 · Cited by 24
Hata, A., Katakami, N., Kaji, R., Fujita, S., & Imai, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318282e047 · Cited by 23
Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas
Strik, W. K. (2008) · Molecular Medicine Reports · doi:10.3892/mmr_00000042 · Cited by 23
Chemotherapy Resistance and Retreatment: A Dogma Revisited
Naing, A., & Kurzrock, R. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.026 · Cited by 23
Guo, R., Chen, X., Wang, T., Zhang, Z., Sun, J., & Shu, Y. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-90 · Cited by 22
Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen
Fornaro, L., Vasile, E., Masi, G., Loupakis, F., Baldi, G. G., Allegrini, G., Salvatore, L., Cremolini, C., Cupini, S., Cortesi, E., et al. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.06.013 · Cited by 19
Revheim, M.-E. R., Kristian, A., Malinen, E., Bruland, Ø. S., Berner, J., Holm, R., Joensuu, H., & Seierstad, T. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.770920 · Cited by 15
de Gramont, A., Chibaudel, B., Bourges, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.4024 · Cited by 14
Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells
Deschatrette, J., Ng, K. H., Gouthière, L., Maigné, J., Guerroui, S., & Wolfrom, C. M. (2004) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000136879.96680.bc · Cited by 8
for The Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, I. C. W. T. C. L. S. G. F. L., Fiegl, M., Falkner, F., Steurer, M., Zojer, N., Hopfinger, G., Haslbauer, F., Winder, G., Voskova, D., Andel, J., et al. (2011) · Annals of Hematology · doi:10.1007/s00277-011-1192-5 · Cited by 8
Second Complete Remission of Relapsed Stage IV Non-Small Cell Lung Cancer Following Retreatment
Yoo, S. J., Lee, J. E., Jung, S. Y., Park, D., Park, M. R., Park, H. S., Jung, S. S., Kim, J. O., & Kim, S. Y. (2012) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2012.72.4.381 · Cited by 2
Blagoev, K. B., Pichun, M. E. B., Wilkerson, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.e14592 · Cited by 1
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738
Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer
Koundouros, N., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00160 · Cited by 415
Metadata
- Authors
- Kuczynski, E. A., Sargent, D. J., Grothey, A., & Kerbel, R. S.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2013-09-03
- Volume
- 10
- Issue
- 10
- Pages
- 571-587
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W1982291583
- Cited by
- 286
- References
- 130
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.